Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9428464-B2
Application number	US-201214241699-A
Country	US
Kind code	B2
Filing date	Aug 28, 2012
Priority date	Aug 30, 2011
Publication date	Aug 30, 2016
Grant date	Aug 30, 2016

Abstract

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

First claim

What is claimed:

1. A compound selected from the group consisting of:
6-Naphthalen-2-yl-pyrimidine-4-carboxylic acid; and
6-Biphenyl-3-yl-pyrimidine-4-carboxylic acid;
or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

3. A method of treating Huntington's disease in a subject in need of such a treatment which method comprises administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignees

• Courtney Stephen Martin
• Prime Michael
• Mitchell William
• Brown Christopher John
• De Aguiar Pena Paula C
• Johnson Peter
• Dominguez Celia
• Toledo-Sherman Leticia M
• Muñoz-Sanjuan Ignacio
• Chdi Foundation Inc

Inventors

• Courtney Stephen Martin
• Prime Michael
• Mitchell William
• Brown Christopher John
• De Aguiar Pena Paula C
• Johnson Peter
• Dominguez Celia
• Toledo-Sherman Leticia M
• Muñoz-Sanjuan Ignacio

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title